Tag: real-world evidence
-
Remdesivir During COVID-19 Hospitalization Linked to Lower Long-Term Mortality in Survivors: Real-World Evidence
Overview: Remdesivir and long-term outcomes after COVID-19 hospitalization Remdesivir (RDV) has been evaluated for short-term benefits in both hospitalized and non-hospitalized patients with COVID-19. However, its impact on long-term outcomes, particularly for patients who survive the initial hospitalization, has been less clear. A real-world study across three health systems in Colorado and Utah examined whether…
-
Remdesivir Linked to Lower Long-Term Mortality After COVID-19 Hospitalization: Real-World Evidence
Overview New real-world data from three health systems in Colorado and Utah suggest that receiving remdesivir (RDV) during a COVID-19–related hospitalization is associated with lower all-cause mortality after discharge. The study analyzed patients who survived their initial hospitalization and followed them for up to 29 months to assess long-term outcomes, including mortality, readmission to hospital,…
-
Remdesivir Linked to Lower Long-Term Mortality After COVID-19 Hospitalization
What the study investigated Researchers examined whether remdesivir (RDV), given during a COVID-19 hospitalization, is associated with reduced mortality after discharge among survivors. Using real-world data from three large health systems in Colorado and Utah, the study followed patients who survived their index hospitalization for 6 to 29 months to assess long-term outcomes beyond the…